Trials show small benefit, but without statistical validity Roche setback leaves Biogen and Eisai as leaders in the field It’s up to Roche’s CEO-designate to revive development fortunes Roche shares down 3.4%, its development partner Morphosys down 29% Nov 14 (Reuters) – Roche’s (ROG.S) Alzheimer’s drug candidate has not been shown to slow the progression …
Roche’s Alzheimer’s drug fails in long-awaited trial Read More »
SHARM EL-SHEIKH, Egypt, November 14 (Reuters) – Countries are far from agreeing on the technical details of the global trade in carbon offset credits after a week of talks at the UN climate summit COP27 in Egypt, according to negotiators and observers, with delays threatening to blow a 2023 deadline. Carbon offsets allow countries or …
COP27: discussions on carbon market rules are slow to start Read More »
WILMINGTON, Del, Nov 14 (Reuters) – A lawsuit opened on Monday over allegations by shareholders that Tesla CEO Elon Musk’s $56 billion pay package was rigged with easy performance targets and that investors were duped into approving it, with Musk expected to take a stand later this week. A Tesla shareholder TSLA.O hopes to prove …
Elon Musk trial opens to decide fate of his $56 billion Tesla salary Read More »
“I can also sell you mushrooms,” he adds. It has become a familiar scene in New York. The state legalized adult marijuana more than a year ago, but has yet to issue a single dispensary license. The result was weed free for all: Cannabis seems to be on sale everywhere – in main shops, bodegas, …
NEW YORK/BOSTON, Nov 11 (Reuters) – Funds adhering to environmental, social and corporate governance (ESG) principles have been hit by unprecedented capital outflows in the market downturn as investors favor preserving the capital to objectives such as the fight against climate change. ESG, a classification applied to fund assets currently worth an estimated $6.5 trillion, …
